Notwithstanding a particularly difficult 2018, Bayer Consumer Health still has "one of the best brand portfolios," and can continue to compete with the market leaders, says CEO Werner Baumann. Consumer Health struggled particularly in the US and Europe in the 12 months, with the majority of its leading brands recording poor performances.
Supply interruptions, stalled attempts to revive its Coppertone and Dr Scholl’s brands and a surprise reverse-switch in China are just some of the reasons why Bayer AG will be glad to see the back of 2018.
Reporting Consumer Health sales in 2018 down by 7.0% - down 0.7% adjusted for portfolio and currency effects – to €5.45bn ($6